June 1, 2026: Over 100 Lawsuits in the GLP-1 NAION MDL, Ozempic Patient Sues After Becoming Blind from NAION The GLP-1 NAION multidistrict litigation now has 110 lawsuits in it, as of June 1, 2026
In a cohort of 7 patients with DT2 and obesity, daily use of liraglutide 1.2mg achieved, after 10 weeks, a weight reduction of 5% and a decrease in BMI of 2kg/m2.80 In another study, 3 patients with DT2 and obesity achieved a decrease in BMI of between 0.8 and 3.8kg/m2 after 18 weeks with this same dose of liraglutide.81 Another 2 patients with obesity and DT2 achieved weight losses of more than 5kg and a decrease in BMI of 1.5 and 2kg/m2 after 6 weeks of treatment.82 Finally, in a series of 20 subjects with obesity and DT2, an average weight loss of 4.7kg was reported after 8 weeks of treatment with liraglutide 1.8mg.83 In most of these patients, improvements in the psoriasis area severity index (PASI) was observed, and on occasions, a decrease in psoriatic plaques
At present: There is no strong evidence that GLP-1 receptor agonists directly cause universal micronutrient deficiency
For use by qualified research professionals only.